A Phase 3 interventional study of Suzetrigine and Placebo (matched to SUZ) in Diabetic Peripheral Neuropathic Pain, sponsored by Vertex Pharmaceuticals Incorporated. Recruiting at 75 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 291 studies in Neuralgia with a site in United States — 50 open to participants now, 61 under way, 5 of them phase 3. Neuralgia · United States.
Among the 291 studies in Neuralgia with a site in United States, this one is the 3rd largest by planned enrollment of the 261 interventional ones that give a count, is one of 13 that started in 2025, is one of 22 in phase 3, reaches primary completion later than 26 of the 60 other live ones, and was the 275th registered.
1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.
Browse Neuralgia studies →50 of the 291 studies in Neuralgia with a site in United States are open now. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 50+
James J. Peters Veterans Affairs Medical Center · Sites in United States
Ages 22+
EicOsis Human Health Inc. · Sites in United States
Ages 18+
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States, Puerto Rico
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
291 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 94 · Phase 3 26 · Phase 4 14
First in 1993; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 734 is above the median of 52 across 832 interventional studies indexed under Neuralgia.
Median enrollment 40 across the 261 interventional studies, 53 across the 28 observational. Of the 193 that completed or were terminated, 86 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 291 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
Vertex Pharmaceuticals Incorporated has 4 studies filed under Neuralgia — fewer than ten, so there is no comparison to draw.
27 of the studies in Neuralgia with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06696443Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) | 2027-01-25 |
| NCT07231419Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy | 2027-04-06 |
| NCT06628908Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy | 2027-05-31 |
| NCT06848348Dogwood Therapeutics Inc.Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain | 2026-12 |
| NCT04865679Axogen CorporationTolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends | 2026-12 |
Add all 27 to your calendar (.ics) → With an account.
Among the 291 studies in Neuralgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine in participants with pain associated with diabetic peripheral neuropathy (DPN).
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized to receive SUZ.
Drug: Suzetrigine
Participants will be randomized to receive placebo matched to SUZ.
Drug: Placebo (matched to SUZ)
Tablets for oral administration
Also known as: VX-548, SUZ
Placebo matched to SUZ for oral administration.
Change From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale (NPRS) at Week 12 Compared to Placebo
Time frame: From Baseline up to Week 12
Change From Baseline in the Medical Outcomes Study 36-item Short-form Health Status (SF-36v2) Physical Component Summary (PCS) Score at Week 12 Compared to Placebo (Pooled with data from Study VX24-548-110)
Time frame: From Baseline up to Week 12
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Apr 2027, 16 months after the start.
Of 33 phase 3 interventional studies under Neuralgia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's planned 16 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Suzetrigine
Vertex Pharmaceuticals Incorporated →